生物相似藥市場:美國付款者的觀點

本報告從新興市場的角度介紹了美國生物相似藥市場，強調了影響其未來的關鍵發展和課題。深入分析付款人對阿達木單抗採用和 Stelara 生物相似藥推出的看法。深入了解 FDA 最新指導對可互換性的影響、自有品牌生物仿製藥的作用以及付款人用來指導其定價和處方決策的策略。它還涵蓋了生物相似藥採用的障礙，例如監管不確定性和原創者策略，並全面概述了這些因素將如何影響市場趨勢和醫療保健節省。

報告內容

• 過去一年發生的事件影響了付款人、醫生和病人對生物相似藥的看法
• 付款人對於阿達木單抗生物相似藥的可用性有何反應？
• 付款人對 Stelara 生物相似藥上市的看法
• 互換性將如何影響處方集的納入以及還存在哪些課題？
• 自有品牌生物相似藥對美國市場的影響
• 付款人如何看待藥局層級的轉換和替代等關鍵問題？
• 美國生物相似藥市場有哪些障礙以及如何克服這些障礙？
• 付款人向生物相似藥公司提供了哪些建議以幫助推動市場發展？

主要企業

Delve into the evolving landscape of the US biosimilars market, focusing on the significant developments and challenges that shape its future. This report provides an in-depth analysis of payer perspectives on the adoption of adalimumab and the anticipated launch of Stelara biosimilars. Gain insights into the impact of recent FDA guidance on interchangeability, the role of private-label co-branded biosimilars and the strategies payers employ to navigate pricing dynamics and formulary decisions. This report also addresses the barriers to biosimilar adoption, such as regulatory uncertainties and originator tactics, offering a comprehensive overview of how these factors influence market trends and healthcare savings.

Key Questions Answered:

• 1. What events have shaped the perception of biosimilars among payers, physicians, and patients in the past year?
• 2. How have payers responded to the coverage of adalimumab biosimilars?
• 3. What are payers' views on the upcoming launch of Stelara biosimilars?
• 4. How has interchangeability influenced formulary inclusions, and what challenges remain?
• 5. What is the impact of private-label co-branded biosimilars on the US market?
• 6. How do payers view key issues like switching and pharmacy-level substitution?
• 7. What barriers remain in the US biosimilars market, and how can they be overcome?
• 8. What advice do payers have for biosimilar companies to drive market evolution?

Key Companies:

Partial List of Participating Experts:

• Payer 1, medical director at a national insurance company that covers over 13 million lives
• Payer 2, chief medical officer at a regional managed care organisation with over 20 years of experience
• Payer 3, pharmacy director at a large national pharmacy benefit manager with 19 years of experience
• Payer 4, medical director with 20 years of experience at a managed care health plan covering 4.5 million lives and specialises in Medicaid business
• Payer 5, chief medical officer and chair of the pharmacy and therapeutics (P&T) committee at a leading managed care organisation with over 25 years of experience
• Payer 6, pharmacy director with 19 years of experience at a leading pharmacy benefit manager
• Payer 7, medical director at a national managed care organisation with over 30 years of experience
• Payer 8, director of pharmacy with over 20 years of experience in managed care, handling a national account with 45 million members, including 2 million Medicaid members

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.